Table 1.
Patient characteristics, positron probe and PET measurements
| No. | Age (yr) | Body weight (kg) | Inj. activity (MBq) | TD (min) | T/B ratio | SUVmean | Histology |
|---|---|---|---|---|---|---|---|
| 1 | 83 | 69 | 93.6 | 153 | 9.0 | 6.8 | Metastasis of papillary thyroid cancer |
| 2 | 40 | 88 | 47.0 | 80 | 3.5 | 5.3 | Gastric adenocarcinoma |
| 3 | 69 | 86 | 65.5 | 133 | 4.9 | 8.3 | Adenocarcinoma of the gastro-oesophageal junction |
| 4 | 56 | 70 | 41.4 | 365 | 3.4 | 6.6 | Recurrent rectal cancer |
| 5 | 43 | 86 | 110.6 | 300 | 3.2 | – | Adenocarcinoma of the colon |
| 6 | 75 | 70 | 44.0 | 140 | 5.2 | – | Adenocarcinoma of the colon |
| 7 | 63 | 89 | 73.6 | 199 | 1.3 | 7.2 | Liver metastasis of colon cancer |
| 8 | 76 | 66 | 48.5 | 149 | 4.1 | 4.1 | Gastric adenocarcinoma |
| 9 | 48 | 72 | 40.7 | 189 | 2.6 | 4.9 | Barret’s cancer |
| 10 | 60 | 86 | 41.1 | 105 | 5.6 | 2.8 | Ductal breast cancer |
| 11 | 57 | 58 | 36.6 | 165 | 10.4 | 2.3 | Adenocarcinoma of the distal oesophagus |
| 12 | 67 | 95 | 52.9 | 149 | 17.2 | – | Adenocarcinoma of the distal oesophagus |
| 13 | 59 | 73 | 36.3 | 250 | 3.3 | 12.8 | Malignant melanoma |
| 14 | 73 | 86 | 37.7 | 19 | 12.3 | 5.0 | Malignant melanoma |
| 15 | 65 | 84 | 36.6 | 171 | 8.4 | 3.8 | Adenocarcinoma of the colon |
| 16 | 71 | 62 | 37.7 | 255 | 16.3 | – | Gastric adenocarcinoma |
| 17 | 53 | 85 | 40.7 | 239 | 11.7 | – | Adenocarcinoma of the gastro-oesophageal junction |
| Mean | 62.3 | 77.9 | 52.0 | 184.3 | 6.6 | 5.8 | |
| SD | 12.0 | 11.0 | 21.7 | 72.2 | 4.8 | 2.8 |
TD time difference between injection and probe measurements, T/B tumour/background ratio, SUVmean mean standardised uptake value in tumour obtained from [18F]FDG PET or PET/CT imaging